Theravance Biopharma Cuts Workforce by 50% Amid Phase 3 Trial Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 03 2026
0mins
Should l Buy TBPH?
Source: stocktwits
- Trial Failure: Theravance Biopharma's CYPRESS study failed to achieve statistical significance on its primary endpoint, leading to the decision to wind down the program, which is expected to have a significant negative impact on future revenues.
- Workforce and Cost Cuts: The company announced a 50% reduction in its workforce and plans to cut operating expenses by about 60%, anticipating one-time cash severance expenses of $5 million to $7 million over the next two quarters.
- Sales Outlook: Despite the challenges, Theravance expects global net sales to reach at least $3.51 billion in 2026, indicating the potential of its product YUPELRI in treating chronic obstructive pulmonary disease.
- Stock Reaction: Theravance's shares plunged nearly 30% following the announcement, breaking below the 200-day moving average for the first time, reflecting the market's pessimism regarding the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TBPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TBPH
Wall Street analysts forecast TBPH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 16.740
Low
13.00
Averages
28.40
High
42.00
Current: 16.740
Low
13.00
Averages
28.40
High
42.00
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Theravance Biopharma Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Theravance Biopharma, Inc. regarding potential securities fraud by the company and its executives, which could lead to significant losses for investors.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that its Phase 3 CYPRESS study for ampreloxetine in patients with multiple system atrophy (MSA) failed to meet its primary endpoint, prompting the company to wind down the program, which could impact its future product pipeline.
- Significant Stock Drop: Following the disappointing clinical trial results, Theravance's stock price plummeted by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, indicating a negative market sentiment towards the company's future prospects.
- Investor Advisory: Pomerantz LLP advises investors who may have suffered losses during this period to contact the firm for information on joining the class action, highlighting the importance of protecting investor rights.
See More
Summers Value Fund LP Reports -2.7% Return in Q1 2026, Underperforming Indices
- Fund Performance Review: The Summers Value Fund LP reported a net return of -2.7% in Q1 2026, significantly underperforming the Russell 2000 Index ETF's 0.9% and the Russell 2000 Value Index ETF's 4.9%, indicating challenges in small-cap investments.
- Key Contributors and Detractors: Major contributors to the fund's performance included Liquidia (LQDA), Avanos Medical (AVNS), and Consensus Cloud Solutions (CCSI), while Electromed (ELMD) and Embecta (EMBC) were the largest detractors, highlighting the portfolio's volatility.
- Investment Strategy Adjustments: The fund initiated a new position in Theravance (TBPH) and exited ADMA Biologics (ADMA) due to the latter's failure to meet expectations, indicating the fund's focus on identifying more attractive investment opportunities.
- Position Strengthening: The fund strengthened its position in Embecta (EMBC) following a sell-off after the company narrowed its fiscal 2026 guidance to the low end of the range, demonstrating the fund's confidence in the stock and its strategic response to market fluctuations.
See More
Theravance Biopharma Under Investigation for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims against Theravance Biopharma, Inc. for potential securities fraud and other unlawful business practices, which could impact the company's reputation and shareholder confidence.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that the CYPRESS study did not meet its primary endpoint for ampreloxetine in treating neurogenic orthostatic hypotension due to multiple system atrophy, leading to the program's termination and potential revenue implications.
- Significant Stock Drop: Following the disappointing trial results, Theravance's stock price fell by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, indicating a pessimistic market outlook on the company's future.
- Potential Legal Consequences: The investigation may result in class action lawsuits against the company, and if fraud is confirmed, it could have significant repercussions on the company's financial health and management, necessitating close monitoring by investors.
See More
Theravance Biopharma Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Theravance Biopharma has engaged in securities fraud or other unlawful business practices, advising investors to contact them for more information, indicating significant legal risks that could impact the company's market reputation.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that its Phase 3 CYPRESS study for ampreloxetine, aimed at treating neurogenic orthostatic hypotension, did not meet its primary endpoint, leading to the decision to wind down the program, which could significantly affect its future product pipeline.
- Stock Price Plunge: Following the disappointing trial results, Theravance's stock price fell by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, reflecting investor pessimism regarding the company's future prospects.
- Potential Legal Consequences: As the investigation unfolds, if misconduct by the company and its executives is confirmed, it could lead to substantial damages and further legal liabilities, imposing financial strain and affecting the company's operational strategies.
See More
Schall Law Firm Investigates Theravance Biopharma for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Theravance Biopharma, focusing on potential violations of securities laws, including false or misleading statements that may affect investor rights.
- Deteriorating Financial Condition: Theravance reported spending millions on operational expenses during the enrollment phase of its CYPRESS trial, indicating significant cash burn on a high-risk program, which ultimately failed and resulted in investor losses.
- Investor Rights Protection: The Schall Law Firm encourages affected investors to participate in the investigation and offers free consultations to help them understand their legal rights and protect their interests.
- Legal Litigation Expertise: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, showcasing its professionalism and influence in the legal field.
See More
Theravance Biopharma Reports Declining R&D Costs Post CYPRESS Enrollment
- Declining R&D Costs: Theravance Biopharma reported a decline in R&D costs following the completion of the CYPRESS trial enrollment, despite incurring $22 million in operating expenses during the trial, indicating significant cash burn on a high-risk program.
- Investor Losses: On March 3, 2026, the company disclosed the failure of its Phase 3 CYPRESS trial, resulting in approximately 26% losses for shareholders, highlighting the company's financial dependence on this trial.
- Legal Consultation Encouraged: The company is encouraging investors who suffered losses to submit their information for legal consultation, reflecting a commitment to investor rights, which may also impact the company's reputation.
- Impact of High-Risk Projects: The failure of the CYPRESS trial not only leads to direct financial losses but may also affect future financing capabilities and investor confidence, further exacerbating the company's financial pressures.
See More
Theravance Biopharma Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Theravance Biopharma, Inc. regarding potential securities fraud by the company and its executives, which could lead to significant losses for investors.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that its Phase 3 CYPRESS study for ampreloxetine in patients with multiple system atrophy (MSA) failed to meet its primary endpoint, prompting the company to wind down the program, which could impact its future product pipeline.
- Significant Stock Drop: Following the disappointing clinical trial results, Theravance's stock price plummeted by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, indicating a negative market sentiment towards the company's future prospects.
- Investor Advisory: Pomerantz LLP advises investors who may have suffered losses during this period to contact the firm for information on joining the class action, highlighting the importance of protecting investor rights.
See More
Summers Value Fund LP Reports -2.7% Return in Q1 2026, Underperforming Indices
- Fund Performance Review: The Summers Value Fund LP reported a net return of -2.7% in Q1 2026, significantly underperforming the Russell 2000 Index ETF's 0.9% and the Russell 2000 Value Index ETF's 4.9%, indicating challenges in small-cap investments.
- Key Contributors and Detractors: Major contributors to the fund's performance included Liquidia (LQDA), Avanos Medical (AVNS), and Consensus Cloud Solutions (CCSI), while Electromed (ELMD) and Embecta (EMBC) were the largest detractors, highlighting the portfolio's volatility.
- Investment Strategy Adjustments: The fund initiated a new position in Theravance (TBPH) and exited ADMA Biologics (ADMA) due to the latter's failure to meet expectations, indicating the fund's focus on identifying more attractive investment opportunities.
- Position Strengthening: The fund strengthened its position in Embecta (EMBC) following a sell-off after the company narrowed its fiscal 2026 guidance to the low end of the range, demonstrating the fund's confidence in the stock and its strategic response to market fluctuations.
See More
Theravance Biopharma Under Investigation for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims against Theravance Biopharma, Inc. for potential securities fraud and other unlawful business practices, which could impact the company's reputation and shareholder confidence.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that the CYPRESS study did not meet its primary endpoint for ampreloxetine in treating neurogenic orthostatic hypotension due to multiple system atrophy, leading to the program's termination and potential revenue implications.
- Significant Stock Drop: Following the disappointing trial results, Theravance's stock price fell by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, indicating a pessimistic market outlook on the company's future.
- Potential Legal Consequences: The investigation may result in class action lawsuits against the company, and if fraud is confirmed, it could have significant repercussions on the company's financial health and management, necessitating close monitoring by investors.
See More
Theravance Biopharma Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Theravance Biopharma has engaged in securities fraud or other unlawful business practices, advising investors to contact them for more information, indicating significant legal risks that could impact the company's market reputation.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that its Phase 3 CYPRESS study for ampreloxetine, aimed at treating neurogenic orthostatic hypotension, did not meet its primary endpoint, leading to the decision to wind down the program, which could significantly affect its future product pipeline.
- Stock Price Plunge: Following the disappointing trial results, Theravance's stock price fell by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, reflecting investor pessimism regarding the company's future prospects.
- Potential Legal Consequences: As the investigation unfolds, if misconduct by the company and its executives is confirmed, it could lead to substantial damages and further legal liabilities, imposing financial strain and affecting the company's operational strategies.
See More
Schall Law Firm Investigates Theravance Biopharma for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Theravance Biopharma, focusing on potential violations of securities laws, including false or misleading statements that may affect investor rights.
- Deteriorating Financial Condition: Theravance reported spending millions on operational expenses during the enrollment phase of its CYPRESS trial, indicating significant cash burn on a high-risk program, which ultimately failed and resulted in investor losses.
- Investor Rights Protection: The Schall Law Firm encourages affected investors to participate in the investigation and offers free consultations to help them understand their legal rights and protect their interests.
- Legal Litigation Expertise: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, showcasing its professionalism and influence in the legal field.
See More
Theravance Biopharma Reports Declining R&D Costs Post CYPRESS Enrollment
- Declining R&D Costs: Theravance Biopharma reported a decline in R&D costs following the completion of the CYPRESS trial enrollment, despite incurring $22 million in operating expenses during the trial, indicating significant cash burn on a high-risk program.
- Investor Losses: On March 3, 2026, the company disclosed the failure of its Phase 3 CYPRESS trial, resulting in approximately 26% losses for shareholders, highlighting the company's financial dependence on this trial.
- Legal Consultation Encouraged: The company is encouraging investors who suffered losses to submit their information for legal consultation, reflecting a commitment to investor rights, which may also impact the company's reputation.
- Impact of High-Risk Projects: The failure of the CYPRESS trial not only leads to direct financial losses but may also affect future financing capabilities and investor confidence, further exacerbating the company's financial pressures.
See More
